Immune checkpoint blockade aims at boosting tumor-specific T cells by breaking immunoevasion mediated by inhibitory checkpoint molecules, such as programmed cell death-1 (PD-1)/PD-ligand 1 (PD-L1). This evidence concerns the gene PDCD1 and neoplasm.